Report: Class-Action Securities Lawsuits Decline But Risks Remain For Life-Sciences Companies

Disgruntled investors lodged fewer securities claims against life-science companies last year. But when they did sue, investors raised familiar issues, often tied to bad news around clinical research and regulatory approvals, according to a law firm report.
The post Report: Class-Action Securities Lawsuits Decline But Risks Remain For Life-Sciences Companies appeared first on Above the Law.
Responses